Peptide Graded

Tirzepatide

Is Tirzepatide safe?

Large trials; GI effects, boxed thyroid warning

AStrong human evidenceFDA approvedas of 2026-10-27

Stomach and gut effects dominate. These are nausea, diarrhea, vomiting, constipation and belly pain. They mostly occur while the dose is raised. In SURMOUNT-1 about 4 to 7 percent of tirzepatide participants stopped because of adverse events. On placebo it was 2.6 percent. Low blood sugar is uncommon unless the drug is combined with insulin or sulfonylureas. 12

The label carries a boxed warning for thyroid C-cell tumors, based on rodent studies. No one knows if this applies to humans. The drug is barred in people with a personal or family history of medullary thyroid cancer. Other warnings include pancreatitis and gallbladder disease. They also include acute kidney injury from dehydration and severe gut disease. People with diabetes face worse diabetic retinopathy. The label also notes that delayed stomach emptying can affect anesthesia. Lean mass loss accompanies fat loss. The effects on muscle over many years are not yet known. 13

A retrospective series from Siena followed 23 adults with bipolar disorder. They started tirzepatide while taking lithium. Average lithium levels rose slightly over the first 12 weeks. Two patients went above the usual upper limit. One stopped tirzepatide after symptomatic lithium toxicity. With 23 patients this is a signal, not an incidence estimate. The authors call for structured monitoring when doctors prescribe the two drugs together. 17

Read the full Tirzepatide page

More on Tirzepatide

Citations

  1. FDA 2025: Mounjaro (tirzepatide) prescribing information accessdata.fda.gov
  2. Jastreboff 2022, NEJM: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) doi.org
  3. FDA 2025: Zepbound (tirzepatide) prescribing information accessdata.fda.gov
  4. FDA 2024: FDA approves first medication for obstructive sleep apnea fda.gov
  5. 2022, Int J Mol Sci: Tirzepatide, a dual GIP/GLP-1 receptor agonist, mechanism and metabolic effects doi.org
  6. 2024, Diabetologia: network meta-analysis of tirzepatide versus semaglutide in type 2 diabetes (28 RCTs) doi.org
  7. Aronne 2024, JAMA: Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4) doi.org
  8. Garvey 2023, Lancet: Tirzepatide once weekly in adults with obesity and type 2 diabetes (SURMOUNT-2) doi.org
  9. FDA Drugs@FDA: Mounjaro NDA 215866 accessdata.fda.gov
  10. FDA 2026: Mounjaro label, pediatric type 2 diabetes accessdata.fda.gov
  11. FDA 2026: Mounjaro label, cardiovascular risk reduction accessdata.fda.gov
  12. FDA Drugs@FDA: Zepbound NDA 217806 accessdata.fda.gov
  13. FDA: Concerns with unapproved GLP-1 drugs used for weight loss fda.gov
  14. Malhotra 2024, NEJM: Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA) doi.org
  15. Jastreboff 2024, NEJM: Tirzepatide for obesity treatment and diabetes prevention, three-year SURMOUNT-1 doi.org
  16. 2025, Cureus: tirzepatide versus semaglutide for weight loss, meta-analysis of seven direct comparative studies doi.org
  17. Rescalli 2026, Hum Psychopharmacol: tirzepatide initiation in lithium-treated bipolar disorder, renal and lithium safety over 12 months pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Tirzepatide article, fact-checked against the cited sources. No dosing anywhere on this site.